Weaver Consulting Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Weaver Consulting Group’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-786	Closed	-$3K	–	1014
2020 Q3	$3K	Hold	786	–	–	﹤0.01%	797
2020 Q2	$2K	Hold	786	–	–	﹤0.01%	835
2020 Q1	$2K	Hold	786	–	–	﹤0.01%	738
2019 Q4	$2K	Hold	786	–	–	﹤0.01%	775
2019 Q3	$2K	Hold	786	–	–	﹤0.01%	754
2019 Q2	$2K	Hold	786	–	–	﹤0.01%	743
2019 Q1	$2K	Buy	+786	New	+$2.65K	﹤0.01%	1352

Other funds holding PDLI

SPC

Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $4.33B AUM 1.35% 1-Year Est. Return

Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Weaver Consulting Group's PDLI Position: Q4 2020 in Review

Weaver Consulting Group sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 786 shares — an estimated $3K sold.

Weaver Consulting Group first reported a position in PDLI in Q1 2019 and held it in 7 quarters. The position peaked at $3K in Q3 2020. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

Weaver Consulting Group reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
Weaver Consulting Group sold 786 PDL BioPharma, Inc. shares in Q4 2020, an estimated $3K.
Weaver Consulting Group first reported a position in PDL BioPharma, Inc. in Q1 2019 and held it in 7 quarters.
Weaver Consulting Group's PDL BioPharma, Inc. position peaked at $3K in Q3 2020.
33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Weaver Consulting Group's 13F filing for Q4 2020, filed 29 Jan 2021.